Developer docs
API playgroundTry for free, no card

Search company profiles

Scorpius Biomanufacturing

Full company profile

uuid00064os

Namestring
Scorpius Biomanufacturing
Legal namestring
Scorpius Holdings, Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Scorpius Biomanufacturing (legally Scorpius Holdings, Inc.) was a contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, specializing in mammalian, microbial, and cell therapy biologics. Founded in 2020 and publicly listed on NYSE American (ticker: SCPX), the company offered GMP manufacturing services, CGMP validation support, and production testing intended to enable clients' BLA submissions. Its customer base was concentrated in the biopharmaceutical vertical, with the only documented engagement being a September 2025 partnership with Tivic Health Systems for CGMP validation of the Entolimod cell line as a treatment for acute radiation syndrome.

The company's revenue model was service-based contract manufacturing for biologic and cell therapy programs, though no pricing or contract-value details were publicly disclosed. Scorpius raised $1.5 million in a March 2024 public offering of 10 million shares at $0.15 per share to fund working capital and general corporate purposes. Despite its public listing, the company was small (51–100 employees), held no documented patents, certifications, or proprietary technology platforms, and operated from a single San Antonio site. The only named executive in the data is Shari Udoff-McDonald, Vice President of Business Development. By early 2026, the company had shuttered operations and its facility was acquired by a subsidiary of a California company, effectively ending the business following a difficult year.

Short descriptiontext

Scorpius Biomanufacturing was a San Antonio-based public CDMO offering GMP mammalian, microbial, and cell therapy manufacturing services to biopharmaceutical clients, including CGMP validation for BLA submissions. The company ceased operations in early 2026 after failing to scale beyond a single named customer engagement.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract biomanufacturing services, biologics CDMO, cell therapy manufacturing, mammalian cell culture, microbial fermentation
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biologics Contract Manufacturing
Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scorpius Biomanufacturing operated as a contract development and manufacturing organization (CDMO) providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services for biologic drug developers. The company offered CGMP production, process validation, and analytical testing services to support client BLA submissions and commercialization of biologic and cell therapy products.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1Mammalian cell culture manufacturing services
CategoryBiologics Manufacturing
Description

Contract manufacturing of biologic drug substances using mammalian cell culture platforms for biopharmaceutical clients developing therapeutic proteins and monoclonal antibodies.

2Microbial fermentation manufacturing services
CategoryBiologics Manufacturing
Description

Contract microbial fermentation production of biologic drug substances for biopharmaceutical clients requiring bacterial or yeast-based expression systems.

3Cell therapy manufacturing services
CategoryCell Therapy Manufacturing
Description

Contract manufacturing of cell therapy products for biopharmaceutical clients developing cell-based therapeutics, supporting process development through commercial production.

4CGMP validation and BLA submission support
CategoryRegulatory and Quality Services
Description

Current Good Manufacturing Practice (CGMP) validation of cell lines, production and analytical testing of therapeutic proteins, and regulatory support services to enable client BLA submissions to the FDA.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-10
Description

Tivic Health Systems partnered with Scorpius Biomanufacturing for GMP validation of its Entolimod cell line. The collaboration involved successful production and testing of Entolimod proteins, a key step toward establishing CGMP manufacturing for BLA submission to advance Entolimod's commercialization as a treatment for acute radiation syndrome.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

WuXi Biologics is one of the largest global CDMOs for biologics, offering end-to-end mammalian and microbial services. Comparable in service offering to Scorpius's biologics CDMO scope, though vastly larger and with a different geographic/customer base.

TypeDirect peer
Description

Vibalogics is a specialized CDMO focused on virotherapy, gene therapy, and viral vector manufacturing, with cell therapy capabilities. Directly comparable to Scorpius's cell therapy and biologics CDMO positioning for advanced therapy developers.

TypeDirect peer
Description

AGC Biologics is a mid-to-large CDMO offering mammalian, microbial, and cell/gene therapy services to biopharma. It is one of the closest direct peers to Scorpius in modality mix and customer profile, though with substantially greater capacity.

TypeBroad incumbent
Description

Catalent is a major CDMO spanning biologics, cell therapies, and fill-finish across multiple modalities. Comparable to Scorpius in the breadth of biologic and cell therapy services it offers to biopharma clients, but at vastly greater scale.

TypeBroad incumbent
Description

Lonza is the world's largest biologics CDMO with extensive mammalian, microbial, and cell & gene therapy capacity. It is the benchmark incumbent that any sub-scale CDMO like Scorpius must position against, and it defines the addressable menu of services Scorpius was attempting to offer.

TypeBroad incumbent
Description

Fujifilm Diosynth is a leading CDMO for mammalian and microbial biologics with large-scale GMP capacity. It is directly comparable to Scorpius's mammalian/microbial CDMO positioning, operating at a much larger scale.

TypeDirect peer
Description

BioVectra is a mid-sized CDMO offering biologics and fermentation-based (microbial) manufacturing plus fill-finish. Directly comparable to Scorpius's mammalian/microbial CDMO positioning and serves a similar small-to-mid biopharma client base.

8KBI Biologics
TypeDirect peer
Description

KBI Biologics is a mid-sized CDMO focused on mammalian and microbial biologics process development and manufacturing. Closely comparable to Scorpius in scale and customer profile for biologic CDMO services.

TypeBroad incumbent
Description

Samsung Biologics is a large-scale mammalian biologics CDMO serving global biopharma. Comparable to Scorpius's mammalian biologics CDMO positioning, but operating at mega-scale with very different capital and capacity economics.

TypeDirect peer
Description

Rentschler Biologics is a mid-sized CDMO specializing in mammalian cell culture biologics manufacturing. Closely comparable to Scorpius in modality (mammalian biologics), service menu, and customer profile, though with stronger financial backing.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scorpius Biomanufacturing

Biologics Contract Manufacturingscorpiusbiologics.com

Scorpius Biomanufacturing was a San Antonio-based public CDMO offering GMP mammalian, microbial, and cell therapy manufacturing services to biopharmaceutical clients, including CGMP validation for BLA submissions. The company ceased operations in early 2026 after failing to scale beyond a single named customer engagement.

What Scorpius Biomanufacturing does

Scorpius Biomanufacturing (legally Scorpius Holdings, Inc.) was a contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, specializing in mammalian, microbial, and cell therapy biologics. Founded in 2020 and publicly listed on NYSE American (ticker: SCPX), the company offered GMP manufacturing services, CGMP validation support, and production testing intended to enable clients' BLA submissions. Its customer base was concentrated in the biopharmaceutical vertical, with the only documented engagement being a September 2025 partnership with Tivic Health Systems for CGMP validation of the Entolimod cell line as a treatment for acute radiation syndrome.

The company's revenue model was service-based contract manufacturing for biologic and cell therapy programs, though no pricing or contract-value details were publicly disclosed. Scorpius raised $1.5 million in a March 2024 public offering of 10 million shares at $0.15 per share to fund working capital and general corporate purposes. Despite its public listing, the company was small (51–100 employees), held no documented patents, certifications, or proprietary technology platforms, and operated from a single San Antonio site. The only named executive in the data is Shari Udoff-McDonald, Vice President of Business Development. By early 2026, the company had shuttered operations and its facility was acquired by a subsidiary of a California company, effectively ending the business following a difficult year.

Scorpius Biomanufacturing firmographics

Firmographics
Name
Scorpius Biomanufacturing
Legal name
Scorpius Holdings, Inc.
Website
https://scorpiusbiologics.com
Company type
Public
Founded year
2020
Operating status
Closed
Headcount range
51–100 employees
Short description
Scorpius Biomanufacturing was a San Antonio-based public CDMO offering GMP mammalian, microbial, and cell therapy manufacturing services to biopharmaceutical clients, including CGMP validation for BLA submissions. The company ceased operations in early 2026 after failing to scale beyond a single named customer engagement.
Ownership category
akta.pro rank

Scorpius Biomanufacturing industry classification

Industry
Product category
Biologics Contract Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract biomanufacturing services
  • Biologics CDMO
  • Cell therapy manufacturing
  • Mammalian cell culture
  • Microbial fermentation

Where Scorpius Biomanufacturing is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Scorpius Biomanufacturing business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Scorpius Biomanufacturing product offering

Product offering

Core offering

Scorpius Biomanufacturing operated as a contract development and manufacturing organization (CDMO) providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services for biologic drug developers. The company offered CGMP production, process validation, and analytical testing services to support client BLA submissions and commercialization of biologic and cell therapy products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mammalian cell culture manufacturing services Contract manufacturing of biologic drug substances using mammalian cell culture platforms for biopharmaceutical clients developing therapeutic proteins and monoclonal antibodies.
  • Microbial fermentation manufacturing services Contract microbial fermentation production of biologic drug substances for biopharmaceutical clients requiring bacterial or yeast-based expression systems.
  • Cell therapy manufacturing services Contract manufacturing of cell therapy products for biopharmaceutical clients developing cell-based therapeutics, supporting process development through commercial production.
  • CGMP validation and BLA submission support Current Good Manufacturing Practice (CGMP) validation of cell lines, production and analytical testing of therapeutic proteins, and regulatory support services to enable client BLA submissions to the FDA.

Companies that use Scorpius Biomanufacturing

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Scorpius Biomanufacturing technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Scorpius Biomanufacturing partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Tivic Health SystemscoreStrategic or Co-development Partner · 10 September 2025Tivic Health Systems partnered with Scorpius Biomanufacturing for GMP validation of its Entolimod cell line. The collaboration involved successful production and testing of Entolimod proteins, a key step toward establishing CGMP manufacturing for BLA submission to advance Entolimod's commercialization as a treatment for acute radiation syndrome.

Scale indicators2 records

Recent moves4 records

Expansion highlights2 records

Scorpius Biomanufacturing competitors and assessment

Company assessment

Broad incumbents

  • WuXi Biologics: WuXi Biologics is one of the largest global CDMOs for biologics, offering end-to-end mammalian and microbial services. Comparable in service offering to Scorpius's biologics CDMO scope, though vastly larger and with a different geographic/customer base.
  • Catalent: Catalent is a major CDMO spanning biologics, cell therapies, and fill-finish across multiple modalities. Comparable to Scorpius in the breadth of biologic and cell therapy services it offers to biopharma clients, but at vastly greater scale.
  • Lonza Group: Lonza is the world's largest biologics CDMO with extensive mammalian, microbial, and cell & gene therapy capacity. It is the benchmark incumbent that any sub-scale CDMO like Scorpius must position against, and it defines the addressable menu of services Scorpius was attempting to offer.
  • Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth is a leading CDMO for mammalian and microbial biologics with large-scale GMP capacity. It is directly comparable to Scorpius's mammalian/microbial CDMO positioning, operating at a much larger scale.
  • Samsung Biologics: Samsung Biologics is a large-scale mammalian biologics CDMO serving global biopharma. Comparable to Scorpius's mammalian biologics CDMO positioning, but operating at mega-scale with very different capital and capacity economics.

Direct peers

  • Vibalogics: Vibalogics is a specialized CDMO focused on virotherapy, gene therapy, and viral vector manufacturing, with cell therapy capabilities. Directly comparable to Scorpius's cell therapy and biologics CDMO positioning for advanced therapy developers.
  • AGC Biologics: AGC Biologics is a mid-to-large CDMO offering mammalian, microbial, and cell/gene therapy services to biopharma. It is one of the closest direct peers to Scorpius in modality mix and customer profile, though with substantially greater capacity.
  • BioVectra: BioVectra is a mid-sized CDMO offering biologics and fermentation-based (microbial) manufacturing plus fill-finish. Directly comparable to Scorpius's mammalian/microbial CDMO positioning and serves a similar small-to-mid biopharma client base.
  • KBI Biologics: KBI Biologics is a mid-sized CDMO focused on mammalian and microbial biologics process development and manufacturing. Closely comparable to Scorpius in scale and customer profile for biologic CDMO services.
  • Rentschler Biologics: Rentschler Biologics is a mid-sized CDMO specializing in mammalian cell culture biologics manufacturing. Closely comparable to Scorpius in modality (mammalian biologics), service menu, and customer profile, though with stronger financial backing.

Market position

Strengths2 records

Weaknesses2 records

Competitive moat2 records

Key risks6 records

Key highlights3 records

Customer concentration

Scorpius Biomanufacturing social profiles

Digital presence

Scorpius Biomanufacturing financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scorpius Biomanufacturing leadership team

Management profile

Number of profiles

Profiles1 record

Scorpius Biomanufacturing funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scorpius Biomanufacturing M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scorpius Biomanufacturing

What does Scorpius Biomanufacturing do?

Scorpius Biomanufacturing operated as a contract development and manufacturing organization (CDMO) providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services for biologic drug developers. The company offered CGMP production, process validation, and analytical testing services to support client BLA submissions and commercialization of biologic and cell therapy products.

Is Scorpius Biomanufacturing a public or private company?

Scorpius Biomanufacturing is a public company. It is classified as public and is currently closed.

When was Scorpius Biomanufacturing founded?

Scorpius Biomanufacturing was founded in 2020. It employs 51 to 100 people.

Where is Scorpius Biomanufacturing based?

Scorpius Biomanufacturing is headquartered in San Antonio, United States, in the North America region.

Who are Scorpius Biomanufacturing's main competitors?

Broad incumbents on record are WuXi Biologics, Catalent, Lonza Group, Fujifilm Diosynth Biotechnologies and Samsung Biologics. Direct peers are Vibalogics, AGC Biologics, BioVectra, KBI Biologics and Rentschler Biologics.

Does Scorpius Biomanufacturing have an API?

No public API is recorded for Scorpius Biomanufacturing.

What industry is Scorpius Biomanufacturing in?

Scorpius Biomanufacturing's product category is Biologics Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NasdaqTivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA FilingTivic Health Systems announced the completion of verification for its Entolimod cell line, the first step in establishing Current Good Manufacturing Practices (CGMP) in preparation for a Biologics License Application (BLA). The company successfully produced new Entolimod proteins with partner Scorpius Biomanufacturing, and in vitro testing confirmed suitable protein structure and yields for larger batch production. CEO Jennifer Ernst called this a significant milestone toward commercialization of Entolimod, which has received Fast Track Designation from the FDA for acute radiation syndrome.ScorpiusbiologicsCutting-Edge Large Molecule cGMP CDMOScorpius BioManufacturing is a U.S. CDMO specializing in cGMP manufacturing and process development for large molecule drugs, with facilities in San Antonio, Texas. The company provides services to emerging biotechs, academic researchers, and U.S. Government institutions, including capabilities for mammalian cell culture and microbial fermentation.AxiosManhattan's biodefense project rises on the plainsManhattan, Kansas, is developing a biodefense hub anchored by the USDA's $1.25 billion NBAF and Kansas State's BRI. Scorpius BioManufacturing plans a new facility there, starting production by 2027, aiming to become the largest U.S.-owned CDMO for large molecules. The project seeks to boost domestic vaccine and countermeasure production.GlobeNewswireNightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating OfficerNightHawk Biosciences promoted Joe Payne to President and COO of its Scorpius BioManufacturing subsidiary. Payne, who joined in 2023 as VP of Quality and Regulatory Affairs, will oversee quality, manufacturing, process sciences, and commercial operations. The company will announce the appointment at DCAT Week in New York City on March 18-21.GlobeNewswireNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramNightHawk Biosciences' Scorpius BioManufacturing subsidiary was awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a publicly traded biotech's Phase 2 clinical program. The scope includes producing a monoclonal antibody in Scorpius' mammalian facility, with completion expected in 2024.NasdaqNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramNightHawk Biosciences announced that its Scorpius BioManufacturing subsidiary secured a multimillion-dollar contract to provide process development, bioanalysis, and cGMP manufacturing services for a publicly traded biotech company's Phase 2 clinical program. The scope of work involves producing a monoclonal antibody at NightHawk's San Antonio facility and is expected to be completed in 2024.GlobeNewswireNightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientNightHawk Biosciences' Scorpius BioManufacturing subsidiary was awarded a preclinical project for a U.S. biotech client, with initial value exceeding $1 million and potential to exceed several million over two years. The work is expected to be completed in 2024, with intent to expand scope for phase 1 trials.GlobeNewswireNightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMONightHawk Biosciences announced a name change to Scorpius Holdings and a ticker change to SCPX, reflecting its shift to a pure-play large-molecule biomanufacturing CDMO. The company also promoted Brian O'Mara and Steve Lavezoli to VP roles and added two new executives. It expects the expansion to generate high incremental margins and attractive returns for shareholders.GlobeNewswireNightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyNightHawk Biosciences announced its Scorpius BioManufacturing subsidiary completed its first manufacturing run for a U.S. biopharmaceutical client at its San Antonio facility. The company expects to recognize revenue from the multi-million-dollar contract during 2024 and plans to expand the agreement after regulatory filings.YahooNightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsNightHawk Biosciences announced a strategic shift to become a pure-play large molecule biomanufacturing CDMO, divesting its Elusys subsidiary and cutting R&D expenses. The company reported over $20 million in signed manufacturing contracts for its Scorpius BioManufacturing subsidiary in 2023, with the divestiture expected to reduce annual operating expenses by more than $13 million.